Amyotrophic Lateral Sclerosis

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

3 days ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

2 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biotechnology, epigenetic therapy, Epigenic, Gene Silencing, Hepatitis B, Hypercholesterolemia, Investments, NRG, Parkinson Disease, Series B funding

Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

3 months ago talkbio0Tagged AMX0035, Amylyx, Amyotrophic Lateral Sclerosis, Clinical trial failure, Discontinuation (procedure), disease program, Infrequent, Placebos, Progressive, Relyvrio, Supranuclear paralysis

Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation

FDA Delays Draw Contrasting Responses: Neurizon Cites Agency Strain, Omeros Takes Softer Tone

3 months ago talkbio0Tagged agency staffing shortages, Amyotrophic Lateral Sclerosis, delays, narsoplimab, NUZ-001, Omeros Corporation, regulatory review, Study on Hold, Transplantation, United States Food and Drug Administration

FDA delays; Neurizon Therapeutics; Omeros Corporation; regulatory review; NUZ-001; narsoplimab; ALS; transplant drugs; agency staffing shortages; clinical hold

FDA Misses IND Deadline for Coya’s ALS Asset, Citing Resource Constraints

4 months ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, Application procedure, Clinical Trials, Coya Therapeutics, Indonesian language, resource shortage, United States Food and Drug Administration

FDA; Coya Therapeutics; IND application; ALS; clinical trial delay; COYA 302; resource shortage

Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, DAZALS trial, dazucorilant, Phase 2 Clinical Trials, SURVEY.ALSFRSR, Survival

Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025

Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact

6 months ago talkbio0Tagged Alchemab, Amyotrophic Lateral Sclerosis, Eli, Eli Lilly

Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

9 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Clinical Trials, Drug Development, Duchenne, Neoplasms, Neuroscience discipline, Schizophrenia

Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

9 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

10 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models